- Home
- BLRX vs TOVX Comparison
BLRX vs TOVX Comparison
Compare BLRX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | TOVX |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.1M |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BLRX | TOVX |
|---|---|---|
| Price | $2.51 | $0.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $1.00 |
| AVG Volume (30 Days) | 17.4K | ★ 494.7K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.16 |
| 52 Week High | $4.56 | $0.86 |
Technical Indicators
Market Signals| Indicator | BLRX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 52.76 |
| Support Level | $2.18 | $0.22 |
| Resistance Level | $3.08 | $0.26 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 4.45 | 43.83 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.